Abstract
Direct attachment of unprotected DOTA (1,4,7,10-tetraazacyclododecane-N',N",N"',N""-tetraacetic acid) to partially suitably protected octreotide or [Tyr3]-octreotide leads after deprotection to [DOTA-DPhe1]-octreotide (III) and [DOTA-DPhe1,Tyr3]-octreotide (IV). These DOTA-containing somatostatin analogs, when labeled with a radiotherapeutic nuclide, are useful as antitumor agents. The partially protected peptides are accessible via solid phase peptide synthesis (SPPS) followed by selective cleavage under mild acidic conditions from the resin.
MeSH terms
-
Drug Carriers
-
Heterocyclic Compounds, 1-Ring / chemical synthesis*
-
Heterocyclic Compounds, 1-Ring / chemistry
-
Heterocyclic Compounds, 1-Ring / pharmacokinetics
-
Humans
-
Indicators and Reagents
-
Iodine Radioisotopes / pharmacokinetics
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Octreotide / analogs & derivatives*
-
Octreotide / chemical synthesis
-
Octreotide / chemistry
-
Octreotide / pharmacokinetics
-
Radiopharmaceuticals / pharmacokinetics*
-
Receptors, Somatostatin / metabolism*
-
Yttrium Radioisotopes / pharmacokinetics
Substances
-
Drug Carriers
-
Heterocyclic Compounds, 1-Ring
-
Indicators and Reagents
-
Iodine Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Somatostatin
-
Yttrium Radioisotopes
-
octreotide, DOTA-Phe(1)-
-
Octreotide
-
Edotreotide